The RB and p53 pathways in cancer.

[1]  J. Slingerland,et al.  Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1 , 2004, Breast Cancer Research and Treatment.

[2]  L. Chin,et al.  Telomere dysfunction provokes regional amplification and deletion in cancer genomes. , 2002, Cancer cell.

[3]  Stephen N. Jones,et al.  E2F1 Induces Phosphorylation of p53 That Is Coincident with p53 Accumulation and Apoptosis , 2002, Molecular and Cellular Biology.

[4]  R. Bernards,et al.  E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. , 2002, Cancer cell.

[5]  S. Lowe,et al.  Oncogenic ras and p53 Cooperate To Induce Cellular Senescence , 2002, Molecular and Cellular Biology.

[6]  David M. Livingston,et al.  A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells , 2002, Science.

[7]  K. Helin,et al.  Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry , 2002, Nature Genetics.

[8]  Soyoung Lee,et al.  A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.

[9]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[10]  F. McCormick,et al.  Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. , 2002, Cancer cell.

[11]  Brian David Dynlacht,et al.  E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. , 2002, Genes & development.

[12]  E. Schmidt,et al.  Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. , 2002, Cancer research.

[13]  A. Lenferink,et al.  ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells , 2002, Molecular and Cellular Biology.

[14]  D. Lane,et al.  Therapeutic exploitation of the p53 pathway. , 2002, Trends in molecular medicine.

[15]  J. Sebolt-Leopold,et al.  Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. , 2002, Trends in molecular medicine.

[16]  E. Sausville.  Complexities in the development of cyclin-dependent kinase inhibitor drugs. , 2002, Trends in molecular medicine.

[17]  B. Druker,et al.  STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.

[18]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[19]  J. Diehl,et al.  p21Cip1 Promotes Cyclin D1 Nuclear Accumulation via Direct Inhibition of Nuclear Export* , 2002, The Journal of Biological Chemistry.

[20]  John T. Powers,et al.  ARF Differentially Modulates Apoptosis Induced by E2F1 and Myc , 2002, Molecular and Cellular Biology.

[21]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[22]  K. Tsai,et al.  ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos , 2002, Current Biology.

[23]  T. van Dyke,et al.  p19ARF Is Dispensable for Oncogenic Stress-Induced p53-Mediated Apoptosis and Tumor Suppression In Vivo , 2002, Molecular and Cellular Biology.

[24]  Jeffrey M. Trimarchi,et al.  Transcription: Sibling rivalry in the E2F family , 2002, Nature Reviews Molecular Cell Biology.

[25]  P. Toogood.  Cyclin‐dependent kinase inhibitors for treating cancer , 2001, Medicinal research reviews.

[26]  F. McCormick,et al.  Cancer gene therapy: fringe or cutting edge? , 2001, Nature Reviews Cancer.

[27]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[28]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[29]  D. Carrasco,et al.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.

[30]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. C. Forrester,et al.  The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. , 2001, Molecular cell.

[32]  F. Zindy,et al.  Differential effects of p19Arf and p16Ink4a loss on senescence of murine bone marrow-derived preB cells and macrophages , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Nevins,et al.  Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. , 2001, Genes & development.

[34]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[35]  A. Yver.  Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. W. Fry,et al.  Cell Cycle and Biochemical Effects of PD 0183812 , 2001, The Journal of Biological Chemistry.

[37]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[38]  C. Korgaonkar,et al.  The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. , 2001, Cancer research.

[39]  D. Fabbro,et al.  Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. , 2001, Journal of the National Cancer Institute.

[40]  L. Chin,et al.  Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.

[41]  J. Shay,et al.  Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. , 2001, Genes & development.

[42]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. W. Fry,et al.  Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6* , 2001 .

[44]  F. Zindy,et al.  Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Jacks,et al.  Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. , 2000, Genes & development.

[46]  A. V. van Rossum,et al.  Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. , 2000, Genes & development.

[47]  Marc J. van de Vijver,et al.  Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers , 2000, Nature Genetics.

[48]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[49]  J. Harbour,et al.  The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.

[50]  R. DePinho,et al.  Cellular Senescence Minireview Mitotic Clock or Culture Shock? , 2000, Cell.

[51]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[52]  J. Shay,et al.  Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology , 2000, Nature Medicine.

[53]  W. Wold,et al.  Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein , 2000, Journal of Virology.

[54]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[55]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[56]  R. DePinho,et al.  Cellular senescence: mitotic clock or culture shock? , 2000, Cell.

[57]  G. Wahl,et al.  Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[58]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[59]  T. Jacks,et al.  The retinoblastoma gene family in differentiation and development , 1999, Oncogene.

[60]  C. Marshall,et al.  How do small GTPase signal transduction pathways regulate cell cycle entry? , 1999, Current opinion in cell biology.

[61]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[62]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[63]  M. Roussel.  The INK4 family of cell cycle inhibitors in cancer , 1999, Oncogene.

[64]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[65]  M. Serrano,et al.  Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras , 1999, Oncogene.

[66]  L. Kedes,et al.  Twist is a potential oncogene that inhibits apoptosis. , 1999, Genes & development.

[67]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[68]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[69]  F. Zindy,et al.  Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. , 1999, Cancer research.

[70]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[71]  Doris Marko,et al.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases , 1999, Nature Cell Biology.

[72]  N. Pavletich.  Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.

[73]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[74]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[75]  M. Oren,et al.  Mdm2: The Ups and Downs , 1999, Molecular medicine.

[76]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[77]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[78]  A. Berns,et al.  Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. , 1999, Genes & development.

[79]  H. Varmus,et al.  Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. , 1998, Genes & development.

[80]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[81]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[82]  Karen H. Vousden,et al.  p14ARF links the tumour suppressors RB and p53 , 1998, Nature.

[83]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[84]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[85]  S. Lowe,et al.  E1A signaling to p53 involves the p19(ARF) tumor suppressor. , 1998, Genes & development.

[86]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[87]  W. Sellers,et al.  Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. , 1998, Genes & development.

[88]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[89]  L. Chin,et al.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. , 1997, Genes & development.

[90]  W. Kaelin,et al.  Role of the retinoblastoma protein in the pathogenesis of human cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  David P. Lane,et al.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.

[92]  J. Massagué,et al.  Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4* , 1997, The Journal of Biological Chemistry.

[93]  Bruno Amati,et al.  Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.

[94]  F. Zindy,et al.  Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging , 1997, Oncogene.

[95]  J. Nevins,et al.  Distinct roles for E2F proteins in cell growth control and apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[96]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[97]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[98]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[99]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[100]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[101]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[102]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[103]  G. Hannon,et al.  Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[104]  D. Lane,et al.  Identification of novel mdm2 binding peptides by phage display. , 1996, Oncogene.

[105]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[106]  G. Peters,et al.  Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.

[107]  A. Deblasio,et al.  Formation of p27-CDK complexes during the human mitotic cell cycle. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[108]  T. Jacks.  Tumor suppressor gene mutations in mice. , 1999, Annual review of genetics.

[109]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[110]  G. Stamp,et al.  Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. , 1995, Genes & development.

[111]  S. Elledge,et al.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.

[112]  W. Lee,et al.  Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis , 1994, Molecular and cellular biology.

[113]  W. Kaelin,et al.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[114]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[115]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[116]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[117]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[118]  A. Levine,et al.  p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. , 1991, Genes & development.

[119]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[120]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.